TY - JOUR
T1 - Assessing the association of diabetes with lung cancer risk
AU - Leiter, Amanda
AU - Charokopos, Antonios
AU - Bailey, Stacyann
AU - Gallagher, Emily J.
AU - Hirsch, Fred R.
AU - LeRoith, Derek
AU - Wisnivesky, Juan P.
N1 - Funding Information:
Peer Review File: Available at https://dx.doi.org/10.21037/ tlcr-21-601 Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi. org/10.21037/tlcr-21-601). EJG is on the advisory board for Novartis and received consulting honorarium from Seattle Genetics and SynDevRx and has received payment for educational events from Infomedica and the American Diabetes Association. FRH reports consulting fees from Bristol-Myers Squibb, Merck, Amgen, AstraZenica/Daiichi, Sanofi, Regeneron, Novartis, OncoCyte, and Genentech, honoraria for lectures from AstraZeneca and Roche, and payment for expert testimony from Gehrson Lehrman Group. JPW received consulting honorarium from Banook, GSK, Sanofi and Atea Pharmaceutical and research grants from Sanofi and Arnold Consultants. The other authors have no conflicts of interest to declare.
Funding Information:
We want to acknowledge the National Cancer Institute Cancer Data Access System, as well as the PLCO investigators for the data provided for this study. Funding: This work was supported by NCI/NIH T32CA225617 (to AL and SB) and Alkeon Capital Management (to EJG).
Publisher Copyright:
© 2021 AME Publishing Company. All rights reserved.
PY - 2021/11
Y1 - 2021/11
N2 - Background: Diabetes is a well-established risk factor for many cancers, but its relationship with lung cancer incidence remains unclear. In this study, we aimed to assess if diabetes is independently associated with lung cancer risk and histology subtype among participants in a screening study. Methods: In a retrospective cohort study using data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) study, we assessed the association of self-reported diabetes with lung cancer incidence using Poisson regression while adjusting for other established risk factors in the PLCOM2012, a validated lung cancer prediction model. The adjusted association of diabetes and lung cancer cell type was evaluated using nominal regression. Stratified analyses were also conducted according to sex, smoking history, and body mass index categories. Results: Overall, 140,395 participants were included in our analysis. Diabetes was not significantly associated with lung cancer incidence [incidence rate ratio (IRR): 1.03, 95% confidence interval (CI): 0.91-1.17]. Similarly, stratified analyses also did not show significant associations between diabetes and lung cancer risk (all P values >0.05). We found no significant difference in the distribution of lung cancer histology in participants with vs. without diabetes (P=0.30). Conclusions: Diabetes was not an independent risk factor for lung cancer in a large cohort of PLCO participants. We did not observe differences in histology according to diabetes status. These results suggest that patients with diabetes do not need more aggressive lung cancer screening. Future research including more detailed metabolic parameters may further elucidate the relationship between metabolic disease and lung cancer risk.
AB - Background: Diabetes is a well-established risk factor for many cancers, but its relationship with lung cancer incidence remains unclear. In this study, we aimed to assess if diabetes is independently associated with lung cancer risk and histology subtype among participants in a screening study. Methods: In a retrospective cohort study using data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) study, we assessed the association of self-reported diabetes with lung cancer incidence using Poisson regression while adjusting for other established risk factors in the PLCOM2012, a validated lung cancer prediction model. The adjusted association of diabetes and lung cancer cell type was evaluated using nominal regression. Stratified analyses were also conducted according to sex, smoking history, and body mass index categories. Results: Overall, 140,395 participants were included in our analysis. Diabetes was not significantly associated with lung cancer incidence [incidence rate ratio (IRR): 1.03, 95% confidence interval (CI): 0.91-1.17]. Similarly, stratified analyses also did not show significant associations between diabetes and lung cancer risk (all P values >0.05). We found no significant difference in the distribution of lung cancer histology in participants with vs. without diabetes (P=0.30). Conclusions: Diabetes was not an independent risk factor for lung cancer in a large cohort of PLCO participants. We did not observe differences in histology according to diabetes status. These results suggest that patients with diabetes do not need more aggressive lung cancer screening. Future research including more detailed metabolic parameters may further elucidate the relationship between metabolic disease and lung cancer risk.
KW - Early detection of cancer
KW - Lung cancer incidence
KW - Lung cancer screening
KW - Lung neoplasms
KW - Metabolic disease and cancer
UR - http://www.scopus.com/inward/record.url?scp=85121153285&partnerID=8YFLogxK
U2 - 10.21037/tlcr-21-601
DO - 10.21037/tlcr-21-601
M3 - Article
AN - SCOPUS:85121153285
VL - 10
SP - 4200
EP - 4208
JO - Translational Lung Cancer Research
JF - Translational Lung Cancer Research
SN - 2226-4477
IS - 11
ER -